Contrasting Dyne Therapeutics (NASDAQ:DYN) & Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Insider & Institutional Ownership

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.8% of Plus Therapeutics shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Plus Therapeutics and Dyne Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$12.98 million	($1.91)	-0.27
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-5.78

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Plus Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Profitability

This table compares Plus Therapeutics and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-357.85%	N/A	-117.72%
Dyne Therapeutics	N/A	-64.12%	-56.75%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Plus Therapeutics and Dyne Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1	1	4	1	2.71
Dyne Therapeutics	1	3	10	4	2.94

Plus Therapeutics presently has a consensus price target of $7.75, suggesting a potential upside of 1,416.63%. Dyne Therapeutics has a consensus price target of $34.93, suggesting a potential upside of 65.09%. Given Plus Therapeutics’ higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than Dyne Therapeutics.

Summary

Dyne Therapeutics beats Plus Therapeutics on 8 of the 13 factors compared between the two stocks.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.